Immunological aspects of pancreatic islet cell transplantation

References

• DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999. Diabet. Med.23, 857–866 (2006).
   PubMed Web of Science ®Google Scholar
• Zipris D. Epidemiology of Type 1 diabetes and what animal models teach us about the role of viruses in disease mechanisms. Clin. Immunol.131, 11–23 (2009).
   PubMed Web of Science ®Google Scholar
• Downing R. Historical review of pancreatic islet transplantation. World J. Surg.8, 137–142 (1984).
   PubMed Web of Science ®Google Scholar
• Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery61, 827–837 (1967).
   PubMed Web of Science ®Google Scholar
• Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes16, 35–39 (1967).
   PubMed Web of Science ®Google Scholar
• Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery72, 175–186 (1972).
   PubMed Web of Science ®Google Scholar
• Sutherland DE, Frenzel E, Payne WD, Matas AJ, Najarian JS. Transplantation of adult islet tissue in rats: spleen vs portal vein site. Surg. Forum.30, 305–307 (1979).
   PubMedGoogle Scholar
• Pyzdrowski KL, Kendall DM, Halter JB, Nakhleh RE, Sutherland DE, Robertson RP. Preserved insulin secretion and insulin independence in recipients of islet autografts. N. Engl. J. Med.327, 220–226 (1992).
   PubMed Web of Science ®Google Scholar
• Sutherland DE. Report of International Human Pancreas and Islet Transplantation Registry Cases through 1981. Diabetes31(Suppl. 4), 112–116 (1982).
   PubMedGoogle Scholar
• Dobroschke J, Schwemmle K, Laube H, Langhoff G, Bretzel RG, Federlin K. Autotransplantation of Langerhans’ islets in a case of total duodenopancreatectomy (author’s translation). Langenbecks Arch. Chir.350, 53–58 (1979).
   PubMedGoogle Scholar
• Grodsinsky C, Malcom S, Goldman J, Dienst S, Oh HK, Westrick P. Islet cell autotransplantation after pancreatectomy for chronic pancreatitis. Its limitations. Arch. Surg.116, 511–516 (1981).
   PubMedGoogle Scholar
• Valente U, Ferro M, Campisi C et al. Report of clinical cases of islet autotransplantation. Transplant Proc.12, 202–204 (1980).
   PubMedGoogle Scholar
• Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes37, 413–420 (1988).
   PubMed Web of Science ®Google Scholar
• Scharp DW, Lacy PE, Santiago JV et al. Insulin independence after islet transplantation into Type I diabetic patient. Diabetes39, 515–518 (1990).
   PubMed Web of Science ®Google Scholar
• Alejandro R, Mintz DH, Noel J et al. Islet cell transplantation in Type I diabetes mellitus. Transplant Proc.19, 2359–2361 (1987).
   PubMed Web of Science ®Google Scholar
• Tzakis AG, Ricordi C, Alejandro R et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet336, 402–405 (1990).
   PubMed Web of Science ®Google Scholar
• Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med.343, 230–238 (2000).
   PubMed Web of Science ®Google Scholar
• Robertson RP, Davis C, Larsen J, Stratta R, Sutherland DE. Pancreas and islet transplantation in Type 1 diabetes. Diabetes Care29, 935 (2006).
   PubMed Web of Science ®Google Scholar
• Ryan EA, Lakey JR, Rajotte RV et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes50, 710–719 (2001).
   PubMed Web of Science ®Google Scholar
• Rickels MR, Schutta MH, Mueller R et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for Type 1 diabetes. Diabetes54, 3205–3211 (2005).
   PubMed Web of Science ®Google Scholar
• Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin. Transpl.45–56 (2008).
   PubMedGoogle Scholar
• Ryan EA, Lakey JR, Paty BW et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes51, 2148–2157 (2002).
   PubMed Web of Science ®Google Scholar
• Robertson RP. Islet transplantation as a treatment for diabetes – a work in progress. N. Engl. J. Med.350, 694–705 (2004).
   PubMed Web of Science ®Google Scholar
• Bennet W, Sundberg B, Groth CG et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes48, 1907–1914 (1999).
   PubMed Web of Science ®Google Scholar
• Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with Type 1 diabetes. Ups. J. Med. Sci.105, 125–133 (2000).
   PubMed Web of Science ®Google Scholar
• Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N. Engl. J. Med.356, 2754–2755 (2007).
   PubMed Web of Science ®Google Scholar
• Griffith RC, Scharp DW, Hartman BK, Ballinger WF, Lacy PE. A morphologic study of intrahepatic portal-vein islet isografts. Diabetes26, 201–214 (1977).
   PubMed Web of Science ®Google Scholar
• Hanley S, Liu S, Lipsett M et al. Tumor necrosis factor-α production by human islets leads to postisolation cell death. Transplantation82, 813–818 (2006).
   PubMedGoogle Scholar
• Johansson U, Olsson A, Gabrielsson S, Nilsson B, Korsgren O. Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem. Biophys. Res. Commun.308, 474–479 (2003).
   PubMed Web of Science ®Google Scholar
• Piemonti L, Leone BE, Nano R et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes51, 55–65 (2002).
   PubMed Web of Science ®Google Scholar
• Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes46, 1733–1742 (1997).
   PubMed Web of Science ®Google Scholar
• Tiedge M, Lortz S, Munday R, Lenzen S. Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes47, 1578–1585 (1998).
   PubMed Web of Science ®Google Scholar
• Tiedge M, Lortz S, Munday R, Lenzen S. Protection against the co-operative toxicity of nitric oxide and oxygen free radicals by overexpression of antioxidant enzymes in bioengineered insulin-producing RINm5F cells. Diabetologia42, 849–855 (1999).
   PubMed Web of Science ®Google Scholar
• Bertera S, Crawford ML, Alexander AM et al. Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. Diabetes52, 387–393 (2003).
   PubMedGoogle Scholar
• Avila J, Barbaro B, Gangemi A et al. Intra-ductal glutamine administration reduces oxidative injury during human pancreatic islet isolation. Am. J. Transplant.5, 2830–2837 (2005).
   PubMedGoogle Scholar
• Thomas DA, Stauffer C, Zhao K et al. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J. Am. Soc. Nephrol.18, 213–222 (2007).
   PubMed Web of Science ®Google Scholar
• Avila JG, Wang Y, Barbaro B et al. Improved outcomes in islet isolation and transplantation by the use of a novel hemoglobin-based O2 carrier. Am. J. Transplant.6, 2861–2870 (2006).
   PubMedGoogle Scholar
• Moberg L, Olsson A, Berne C et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation76, 1285–1288 (2003).
   PubMedGoogle Scholar
• Moberg L, Johansson H, Lukinius A et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet360, 2039–2045 (2002).
   PubMed Web of Science ®Google Scholar
• Johansson H, Lukinius A, Moberg L et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes54, 1755–1762 (2005).
   PubMed Web of Science ®Google Scholar
• Nilsson B, Berne C, Korsgren O. The recent finding that tissue factor is produced by the pancreatic islets constitutes a possible link between insulin resistance and cardiovascular disease. Am. J. Ther.12, 551–554 (2005).
   PubMedGoogle Scholar
• Moberg L, Korsgren O, Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin. Exp. Immunol.142, 125–131 (2005).
   PubMedGoogle Scholar
• Ehrnfelt C, Kumagai-Braesch M, Uzunel M, Holgersson J. Adult porcine islets produce MCP-1 and recruit human monocytes in vitro. Xenotransplantation11, 184–194 (2004).
   PubMed Web of Science ®Google Scholar
• Oberholzer J, Yu D, Triponez F et al. Decomplementation with cobra venom factor prolongs survival of xenografted islets in a rat to mouse model. Immunology97, 173–180 (1999).
   PubMedGoogle Scholar
• Badet L, Titus T, Metzen E et al. The interaction between primate blood and mouse islets induces accelerated clotting with islet destruction. Xenotransplantation9, 91–96 (2002).
   PubMedGoogle Scholar
• Kirchhof N, Shibata S, Wijkstrom M et al. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation11, 396–407 (2004).
   PubMed Web of Science ®Google Scholar
• Tjernberg J, Ekdahl KN, Lambris JD, Korsgren O, Nilsson B. Acute antibody-mediated complement activation mediates lysis of pancreatic islets cells and may cause tissue loss in clinical islet transplantation. Transplantation85, 1193–1199 (2008).
   PubMed Web of Science ®Google Scholar
• Titus TT, Horton PJ, Badet L et al. Adverse outcome of human islet–allogeneic blood interaction. Transplantation75, 1317–1322 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidt P, Goto M, Le Mauff B, Anegon I, Korsgren O. Adenovirus-mediated expression of human CD55 or CD59 protects adult porcine islets from complement-mediated cell lysis by human serum. Transplantation75, 697–702 (2003).
   PubMedGoogle Scholar
• Fodor WL, Williams BL, Matis LA et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl Acad. Sci. USA91, 11153–11157 (1994).
   PubMed Web of Science ®Google Scholar
• Bennet W, Bjorkland A, Sundberg B et al. Expression of complement regulatory proteins on islets of Langerhans: a comparison between human islets and islets isolated from normal and hDAF transgenic pigs. Transplantation72, 312–319 (2001).
   PubMedGoogle Scholar
• Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson B. Low-molecular weight dextran sulfate abrogates the instant blood-mediated inflammatory reaction induced by adult porcine islets both in vitro and in vivo. Transplant Proc.36, 1186–1187 (2004).
   PubMed Web of Science ®Google Scholar
• Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J. Immunol.159, 1953–1960 (1997).
   PubMed Web of Science ®Google Scholar
• Ormsby RJ, Jokiranta TS, Duthy TG et al. Localization of the third heparin-binding site in the human complement regulator factor H1. Mol. Immunol.43, 1624–1632 (2006).
   PubMed Web of Science ®Google Scholar
• Pangburn MK, Atkinson MA, Meri S. Localization of the heparin-binding site on complement factor H. J. Biol. Chem.266, 16847–16853 (1991).
   PubMedGoogle Scholar
• Laumonier T, Walpen AJ, Maurus CF et al. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. Transplantation76, 838–843 (2003).
   PubMedGoogle Scholar
• Banz Y, Hess OM, Robson SC et al. Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury. Eur. Heart J.26, 2334–2343 (2005).
   PubMedGoogle Scholar
• Spirig R, van Kooten C, Obregon C, Nicod L, Daha M, Rieben R. The complement inhibitor low molecular weight dextran sulfate prevents TLR4-induced phenotypic and functional maturation of human dendritic cells. J. Immunol.181, 878–890 (2008).
   PubMedGoogle Scholar
• Schmidt P, Magnusson C, Lundgren T, Korsgren O, Nilsson B. Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor. Transplantation86, 1523–1530 (2008).
   PubMed Web of Science ®Google Scholar
• Johansson H, Goto M, Dufrane D et al. Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation. Am. J. Transplant.6, 305–312 (2006).
   PubMedGoogle Scholar
• Spirig R, Gajanayake T, Korsgren O, Nilsson B, Rieben R. Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. Mol. Immunol.45, 4084–4094 (2008).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Goto M, Ogawa N et al. Superiority of fresh islets compared with cultured islets. Transplant Proc.41, 350–351 (2009).
   PubMedGoogle Scholar
• Takahashi H, Goto M, Ogawa N et al. Influence of a current style of culture on the quality of isolated pancreatic islets. Transplant Proc.40, 358–359 (2008).
   PubMedGoogle Scholar
• Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes51, 1779–1784 (2002).
   PubMed Web of Science ®Google Scholar
• Testa L, Bhindi R, Agostoni P, Abbate A, Zoccai GG, van Gaal WJ. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin. Drug. Saf.6, 397–406 (2007).
   PubMed Web of Science ®Google Scholar
• Contreras JL, Eckstein C, Smyth CA et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes53, 2804–2814 (2004).
   PubMed Web of Science ®Google Scholar
• Cui W, Wilson JT, Wen J et al. Thrombomodulin improves early outcomes after intraportal islet transplantation. Am. J. Transplant.9, 1308–1316 (2009).
   PubMedGoogle Scholar
• Cabric S, Sanchez J, Lundgren T et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes56, 2008–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9, 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Plotnikov AN, Ibrahimi OA et al. Crystal structure of a ternary FGF–FGFR–heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell.6, 743–750 (2000).
   PubMed Web of Science ®Google Scholar
• Cabric S, Elgue G, Nilsson B, Korsgren O, Schmidt P. Adenovirus-mediated expression of the anticoagulant hirudin in human islets: a tool to make the islets biocompatible to blood. Cell. Transplant.15, 759–767 (2006).
   PubMedGoogle Scholar
• Dwyer KM, Mysore TB, Crikis S et al. The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation82, 428–432 (2006).
   PubMed Web of Science ®Google Scholar
• Ueki M, Yasunami Y, Arima T, Motoyama K, Ikeda S, Tanaka M. Protection of intrahepatic islet grafts from hyperglycemic toxicity by nicotinamide treatment. Transplant Proc.27, 618 (1995).
   PubMedGoogle Scholar
• Jung DY, Park JB, Joo SY et al. Effect of nicotinamide on early graft failure following intraportal islet transplantation. Exp. Mol. Med.41(11), 782–92 (2009).
   PubMedGoogle Scholar
• Ichii H, Wang X, Messinger S et al. Improved human islet isolation using nicotinamide. Am. J. Transplant.6, 2060–2068 (2006).
   PubMed Web of Science ®Google Scholar
• Vaca P, Berna G, Martin F, Soria B. Nicotinamide induces both proliferation and differentiation of embryonic stem cells into insulin-producing cells. Transplant Proc.35, 2021–2023 (2003).
   PubMedGoogle Scholar
• Vaca P, Berna G, Araujo R et al. Nicotinamide induces differentiation of embryonic stem cells into insulin-secreting cells. Exp. Cell Res.314, 969–974 (2008).
   PubMed Web of Science ®Google Scholar
• Johansson U, Elgue G, Nilsson B, Korsgren O. Composite islet–endothelial cell grafts: a novel approach to counteract innate immunity in islet transplantation. Am. J. Transplant.5, 2632–2639 (2005).
   PubMedGoogle Scholar
• Toso C, Serre-Beinier V, Emamaullee J et al. The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation86, 1361–1369 (2008).
   PubMed Web of Science ®Google Scholar
• Nitta T, Itoh T, Matsuoka N et al. Prevention of early loss of transplanted islets in the liver of mice by adenosine. Transplantation88, 49–56 (2009).
   PubMedGoogle Scholar
• Connolly JE. Pancreatic whole organ transplantation. Surg. Clin. North Am.58, 383–390 (1978).
   PubMedGoogle Scholar
• Brooks-Worrell BM, Peterson KP, Peterson CM, Palmer JP, Jovanovic L. Reactivation of Type 1 diabetes in patients receiving human fetal pancreatic tissue transplants without immunosuppression. Transplantation69, 1824–1829 (2000).
   PubMedGoogle Scholar
• Stegall MD, Loberman Z, Ostrowska A, Coulombe M, Gill RG. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody. J. Surg. Res.64, 156–160 (1996).
   PubMedGoogle Scholar
• Okitsu T, Bartlett ST, Hadley GA, Drachenberg CB, Farney AC. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am. J. Transplant.1, 138–145 (2001).
   PubMedGoogle Scholar
• Makhlouf L, Kishimoto K, Smith RN et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes51, 3202–3210 (2002).
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, Bottazzo GF, Freedman ZR, Lernmark A, Zuhlke H, Groth CG. Allogeneic rejection or recurrence of autoimmunity as the cause of immune destruction of pancreatic grafts. Transplant Proc.12, 112–113 (1980).
   PubMedGoogle Scholar
• Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N. Engl. J. Med.335, 860–863 (1996).
   PubMedGoogle Scholar
• Martin-Pagola A, Sisino G, Allende G et al. Insulin protein and proliferation in ductal cells in the transplanted pancreas of patients with Type 1 diabetes and recurrence of autoimmunity. Diabetologia51, 1803–1813 (2008).
   PubMed Web of Science ®Google Scholar
• Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin. Immunol.128, 23–30 (2008).
   PubMedGoogle Scholar
• Santamaria P, Nakhleh RE, Sutherland DE, Barbosa JJ. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes41, 53–61 (1992).
   PubMed Web of Science ®Google Scholar
• Roep BO, Stobbe I, Duinkerken G et al. Auto- and alloimmune reactivity to human islet allografts transplanted into Type 1 diabetic patients. Diabetes48, 484–490 (1999).
   PubMed Web of Science ®Google Scholar
• Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab. Invest.53, 132–144 (1985).
   PubMed Web of Science ®Google Scholar
• Stegall MD, Lafferty KJ, Kam I, Gill RG. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation61, 1272–1274 (1996).
   PubMed Web of Science ®Google Scholar
• Jaeger C, Hering BJ, Hatziagelaki E, Federlin K, Bretzel RG. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression. J. Mol. Med.77, 45–48 (1999).
   PubMed Web of Science ®Google Scholar
• Vantyghem MC, Fajardy I, Pigny P et al. Kinetics of diabetes-associated autoantibodies after sequential intraportal islet allograft associated with kidney transplantation in Type 1 diabetes. Diabetes Metab.29, 595–601 (2003).
   PubMedGoogle Scholar
• Bosi E, Braghi S, Maffi P et al. Autoantibody response to islet transplantation in Type 1 diabetes. Diabetes50, 2464–2471 (2001).
   PubMed Web of Science ®Google Scholar
• Makhlouf L, Yamada A, Ito T et al. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J. Am. Soc. Nephrol.14, 2168–2175 (2003).
   PubMedGoogle Scholar
• Woehrle M, Markmann JF, Silvers WK, Barker CF, Naji A. Transplantation of cultured pancreatic islets to BB rats. Surgery100, 334–341 (1986).
   PubMedGoogle Scholar
• Markmann JF, Posselt AM, Bassiri H et al. Major-histocompatibility-complex restricted and nonrestricted autoimmune effector mechanisms in BB rats. Transplantation52, 662–667 (1991).
   PubMedGoogle Scholar
• Molano RD, Pileggi A, Berney T et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. Transplantation75, 1812–1819 (2003).
   PubMed Web of Science ®Google Scholar
• Fu F, Hu S, Deleo J et al. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation73, 1425–1430 (2002).
   PubMed Web of Science ®Google Scholar
• Kuttler B, Rosing K, Lehmann M, Brock J, Hahn HJ. Prevention of autoimmune but not allogeneic destruction of grafted islets by different therapeutic strategies. J. Mol. Med.77, 226–229 (1999).
   PubMedGoogle Scholar
• Makhlouf L, Grey ST, Dong V et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation77, 990–997 (2004).
   PubMed Web of Science ®Google Scholar
• Guo Z, Wu T, Kirchhof N et al. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation71, 1656–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Drage M, Zaccone P, Phillips JM et al. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice. Transplantation74, 611–619 (2002).
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon WL, Rabinovitch A. Combination therapy with epidermal growth factor and gastrin delays autoimmune diabetes recurrence in nonobese diabetic mice transplanted with syngeneic islets. Transplant Proc.40, 529–532 (2008).
   PubMed Web of Science ®Google Scholar
• Bartlett ST, Schweitzer EJ, Kuo PC, Johnson LB, Delatorre A, Hadley GA. Prevention of autoimmune islet allograft destruction by engraftment of donor T cells. Transplantation63, 299–303 (1997).
   PubMedGoogle Scholar
• Georgiou HM, Constantinou D, Mandel TE. Prevention of autoimmunity in nonobese diabetic (NOD) mice by neonatal transfer of allogeneic thymic macrophages. Autoimmunity21, 89–97 (1995).
   PubMed Web of Science ®Google Scholar
• Li H, Kaufman CL, Ildstad ST. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice. Surgery118, 192–197; discussion 7–8 (1995).
   PubMed Web of Science ®Google Scholar
• Seung E, Iwakoshi N, Woda BA et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood95, 2175–2182 (2000).
   PubMed Web of Science ®Google Scholar
• Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes53, 376–383 (2004).
   PubMed Web of Science ®Google Scholar
• Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med.358, 362–368 (2008).
   PubMed Web of Science ®Google Scholar
• Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med.358, 353–361 (2008).
   PubMed Web of Science ®Google Scholar
• Wang T, Singh B, Warnock GL, Rajotte RV. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes41, 114–117 (1992).
   PubMedGoogle Scholar
• Qu P, Ji RC, Shimoda H, Miura M, Kato S. Study on pancreatic lymphatics in nonobese diabetic mouse with prevention of insulitis and diabetes by adjuvant immunotherapy. Anat. Rec. A. Discov. Mol. Cell. Evol. Biol.281, 1326–1336 (2004).
   PubMedGoogle Scholar
• Lakey JR, Singh B, Warnock GL, Rajotte RV. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. Transplantation57, 1213–1217 (1994).
   PubMedGoogle Scholar
• Casteels K, Waer M, Laureys J et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation65, 1225–1232 (1998).
   PubMed Web of Science ®Google Scholar
• Orive G, Hernandez RM, Rodriguez Gascon A et al. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol.22, 87–92 (2004).
   PubMed Web of Science ®Google Scholar
• Chick WL, Like AA, Lauris V. β cell culture on synthetic capillaries: an artificial endocrine pancreas. Science187, 847–849 (1975).
   PubMed Web of Science ®Google Scholar
• Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science210, 908–910 (1980).
   PubMed Web of Science ®Google Scholar
• Canaple L, Rehor A, Hunkeler D. Improving cell encapsulation through size control. J. Biomater. Sci. Polym. Ed.13, 783–796 (2002).
   PubMed Web of Science ®Google Scholar
• Campos-Lisboa AC, Mares-Guia TR, Grazioli G, Goldberg AC, Sogayar MC. Biodritin microencapsulated human islets of Langerhans and their potential for Type 1 diabetes mellitus therapy. Transplant Proc.40, 433–435 (2008).
   PubMedGoogle Scholar
• Kobayashi T, Aomatsu Y, Iwata H et al. Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression. Transplantation75, 619–625 (2003).
   PubMed Web of Science ®Google Scholar
• Dufrane D, Goebbels RM, Saliez A, Guiot Y, Gianello P. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation81, 1345–1353 (2006).
   PubMed Web of Science ®Google Scholar
• Duvivier-Kali VF, Omer A, Lopez-Avalos MD, O’Neil JJ, Weir GC. Survival of microencapsulated adult pig islets in mice in spite of an antibody response. Am. J. Transplant.4, 1991–2000 (2004).
   PubMedGoogle Scholar
• Tuch BE, Keogh GW, Williams LJ et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care32(10), 1887–1889 (2009).
   PubMed Web of Science ®Google Scholar
• Mallett AG, Korbutt GS. Alginate modification improves long-term survival and function of transplanted encapsulated islets. Tissue Eng. Part A.15, 1301–1309 (2009).
   PubMed Web of Science ®Google Scholar
• Barnett BP, Arepally A, Karmarkar PV et al. Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat. Med.13, 986–991 (2007).
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Morel P, Condie R et al. Beneficial and detrimental effects of RBC-adsorbed antilymphocyte globulin and prednisone on purified canine islet autograft and allograft function. Transplantation51, 37–42 (1991).
   PubMedGoogle Scholar
• Gangemi A, Salehi P, Hatipoglu B et al. Islet transplantation for brittle Type 1 diabetes: the UIC protocol. Am. J. Transplant.8, 1250–1261 (2008).
   PubMedGoogle Scholar
• Froud T, Faradji RN, Pileggi A et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation86, 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Froud T, Baidal DA, Faradji R et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation86, 1695–1701 (2008).
   PubMed Web of Science ®Google Scholar
• Bellin MD, Kandaswamy R, Parkey J et al. Prolonged insulin independence after islet allotransplants in recipients with Type 1 diabetes. Am. J. Transplant.8, 2463–2470 (2008).
   PubMedGoogle Scholar
• Fowler M, Virostko J, Chen Z et al. Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation79, 768–776 (2005).
   PubMedGoogle Scholar
• Lu Y, Dang H, Middleton B et al. Bioluminescent monitoring of islet graft survival after transplantation. Mol. Ther.9, 428–435 (2004).
   PubMedGoogle Scholar
• Virostko J, Chen Z, Fowler M, Poffenberger G, Powers AC, Jansen ED. Factors influencing quantification of in vivo bioluminescence imaging: application to assessment of pancreatic islet transplants. Mol. Imaging3, 333–342 (2004).
   PubMedGoogle Scholar
• Kim SJ, Doudet DJ, Studenov AR et al. Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat. Med.12, 1423–1428 (2006).
   PubMedGoogle Scholar
• Toso C, Zaidi H, Morel P et al. Assessment of 18F-FDG-leukocyte imaging to monitor rejection after pancreatic islet transplantation. Transplant Proc.38, 3033–3034 (2006).
   PubMedGoogle Scholar
• Eich T, Eriksson O, Sundin A et al. Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation84, 893–898 (2007).
   PubMed Web of Science ®Google Scholar
• Evgenov NV, Pratt J, Pantazopoulos P, Moore A. Effects of glucose toxicity and islet purity on in vivo magnetic resonance imaging of transplanted pancreatic islets. Transplantation85, 1091–1098 (2008).
   PubMed Web of Science ®Google Scholar
• Hathout E, Sowers L, Wang R et al.In vivo magnetic resonance imaging of vascularization in islet transplantation. Transpl. Int.20, 1059–1065 (2007).
   PubMedGoogle Scholar
• Medarova Z, Moore A. Non-invasive detection of transplanted pancreatic islets. Diabetes Obes. Metab.10(Suppl. 4), 88–97 (2008).
   PubMedGoogle Scholar
• Frank A, Deng S, Huang X et al. Transplantation for Type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann. Surg.240, 631–640; discussion 640–643 (2004).
   PubMed Web of Science ®Google Scholar
• Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin. Transpl.19, 433–455 (2005).
   PubMed Web of Science ®Google Scholar
• Sollinger HW, Vernon WB, D’Alessandro AM, Kalayoglu M, Stratta RJ, Belzer FO. Combined liver and pancreas procurement with Belzer-UW solution. Surgery106, 685–690; discussion 690–691 (1989).
   PubMed Web of Science ®Google Scholar
• Lakey JR, Tsujimura T, Shapiro AM, Kuroda Y. Preservation of the human pancreas before islet isolation using a two-layer (UW solution-perfluorochemical) cold storage method. Transplantation74, 1809–1811 (2002).
   PubMedGoogle Scholar
• Lakey JR, Helms LM, Kin T et al. Serine-protease inhibition during islet isolation increases islet yield from human pancreases with prolonged ischemia. Transplantation72, 565–570 (2001).
   PubMed Web of Science ®Google Scholar
• Bucher P, Mathe Z, Morel P et al. Assessment of a novel two-component enzyme preparation for human islet isolation and transplantation. Transplantation79, 91–97 (2005).
   PubMed Web of Science ®Google Scholar
• Bucher P, Mathe Z, Bosco D et al. Serva collagenase NB1: a new enzyme preparation for human islet isolation. Transplant Proc.36, 1143–1144 (2004).
   PubMed Web of Science ®Google Scholar
• Quan N, Ho E, La W, Tsai YH, Bray T. Administration of NF-κB decoy inhibits pancreatic activation of NF-κB and prevents diabetogenesis by alloxan in mice. FASEB J.15, 1616–1618 (2001).
   PubMedGoogle Scholar
• Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-κB activation in insulin-producing cells. Diabetes52, 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J. Leukoc. Biol.77, 587–597 (2005).
   PubMed Web of Science ®Google Scholar
• Olsson R, Carlsson PO. Better vascular engraftment and function in pancreatic islets transplanted without prior culture. Diabetologia48, 469–476 (2005).
   PubMed Web of Science ®Google Scholar
• Olsson R, Maxhuni A, Carlsson PO. Revascularization of transplanted pancreatic islets following culture with stimulators of angiogenesis. Transplantation82, 340–347 (2006).
   PubMedGoogle Scholar
• Johansson A, Sandvik D, Carlsson PO. Inhibition of p38 MAP kinase in the early posttransplantation phase redistributes blood vessels from the surrounding stroma into the transplanted endocrine tissue. Cell. Transplant.15, 483–488 (2006).
   PubMedGoogle Scholar
• Markmann JF, Jacobson J, Kimura H, Brayman KL, Barker CF, Naji A. Prevention of autoimmune damage to islet grafts in BB rats by antibody therapy. Transplant Proc.21, 2703–2704 (1989).
   PubMedGoogle Scholar
• Maki T, Ichikawa T, Blanco R, Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc. Natl Acad. Sci. USA89, 3434–3438 (1992).
   PubMed Web of Science ®Google Scholar
• Kover KL, Geng Z, Hess D, Benjamin C, Moore WV. CD40/154 blockade and rejection of islet allografts in the streptozotocin and autoimmune diabetic rat. Pediatr. Diabetes2, 178–183 (2001).
   PubMedGoogle Scholar
• Molano RD, Pileggi A, Berney T et al. Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes52, 957–964 (2003).
   PubMedGoogle Scholar
• Posselt AM, Naji A, Roark JH, Markmann JF, Barker CF. Intrathymic islet transplantation in the spontaneously diabetic BB rat. Ann. Surg.214, 363–371; discussion 71–73 (1991).
   PubMedGoogle Scholar
• Wang H, Lee SS, Gao W et al. Donor treatment with carbon monoxide can yield islet allograft survival and tolerance. Diabetes54, 1400–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Wang H, Lee SS, Dell’Agnello C et al. Bilirubin can induce tolerance to islet allografts. Endocrinology147, 762–768 (2006).
   PubMedGoogle Scholar
• Sakuma Y, Ricordi C, Miki A et al. Effect of pituitary adenylate cyclase-activating polypeptide in islet transplantation. Transplant Proc.41, 343–345 (2009).
   PubMedGoogle Scholar
• Hiramatsu S, Hoog A, Moller C, Grill V. Treatment with diazoxide causes prolonged improvement of β-cell function in rat islets transplanted to a diabetic environment. Metabolism49, 657–661 (2000).
   PubMedGoogle Scholar
• Wang X, Alfrey EJ, Posselt A, Tafra L, Alak AM, Dafoe DC. Intraportal delivery of immunosuppression to intrahepatic islet allograft recipients. Transpl. Int.8, 268–272 (1995).
   PubMedGoogle Scholar
• Arita S, Kasraie A, Une S, Ohtsuka S, Smith CV, Mullen Y. Prolongation of islet allograft survival in mice by combined treatment with pravastatin and low-dose cyclosporine. Cell. Transplant.10, 639–644 (2001).
   PubMedGoogle Scholar
• Farkas G, Szasz Z, Lazar G Jr, Csanadi J, Lazar G. Macrophage blockade induced by repeated gadolinium chloride injections saves human fetal islet xenografting in rats. Transplant Proc.34, 1460–1461 (2002).
   PubMedGoogle Scholar